Sysmex and Hitachi High-Tech agree to collaborate on development of new genetic testing systems
Collaboration aims to expand optimal genetic testing for individual diseases
19 Mar 2024
Sysmex Corporation and Hitachi High-Tech Corporation have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers). This decision comes from discussions based on the findings of joint research carried out since the conclusion of a feasibility study (FS) agreement in August 2023 aimed at developing new genetic testing systems.
To achieve widespread clinical realization, Sysmex and Hitachi High-Tech will develop more efficient genetic testing systems at a lower cost, aiming at expanding optimal genetic testing for individual diseases.
In recent years, there has been active development of assay reagents using next-generation sequencers in the genetic testing field. However, such challenges as shortening measurement times and reducing running costs have emerged, necessitating the development of new genetic testing systems that can be widely adopted in the clinical setting.
In order to resolve these issues, the companies concluded the FS agreement in August 2023 to jointly develop new genetic testing systems enabling optimal genetic analysis for individual diseases by combining Hitachi High-Tech's CE sequencer technology and Sysmex's knowledge of NGS reagent development and analysis technology.
Hitachi High-Tech will proceed with obtaining approval for CE sequencers as medical devices, and Sysmex will go ahead with development and regulatory approval for testing reagents for use with such devices, and develop analysis software. Both companies will first work on clinical application in the oncology area and then aim to expand gradually to other disease areas.